store at low temperature | store at -20°C
Mogamulizumab (KW-0761) 是一种针对 T 细胞 CC 趋化因子受体 4 的 单克隆抗体。Mogamulizumab 具有抗癌活性,通过抗体依赖性细胞毒性 (ADCC) 消除肿瘤细胞,可用于研究癌症、成人T细胞白血病/淋巴瘤 (ATLL)、皮肤T细胞淋巴瘤(CTCL)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,290 | 现货 | ||
5 mg | ¥ 6,630 | 现货 | ||
10 mg | ¥ 8,930 | 现货 | ||
25 mg | ¥ 13,200 | 现货 | ||
50 mg | ¥ 17,900 | 现货 | ||
100 mg | ¥ 23,900 | 现货 |
产品描述 | Mogamulizumab (KW-0761) is a monoclonal antibody against T cell CC chemokine receptor 4. Mogamulizumab has anticancer activity, eliminating tumor cells through antibody dependent cytotoxicity (ADCC), and can be used to study cancer, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). |
体外活性 |
In the presence of PBMCs, Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3)[2]. In PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation[3]. Cultured PBMCs from patients with HAM/TSP treated with Mogamulizumab (1 μg/mL, 5 days) eliminate CD4+CCR4+ T cells[3]. |
体内活性 |
In a murine xenograft model, Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) inhibits the growth of EBV-positive NK-cell lymphomas when combined with PBMC transplantation[2]. In a canine bladder cancer-engrafted mouse model, Mogamulizumab (0.1 mg/kg, i.v., every other day) combined with canine PBMCs (administered every fourth day) inhibits tumor growth[4]. Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells in dogs, with no observed adverse effects[4]. |
别名 | KW-0761 |
分子量 | N/A |
CAS No. | 1159266-37-1 |
store at low temperature | store at -20°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mogamulizumab 1159266-37-1 Autophagy GPCR/G Protein Immunology/Inflammation CXCR KW-0761 KW 0761 KW0761 Inhibitor inhibitor inhibit